The journal shared a new study comparing GLP-1 receptor agonists on the risk of heart rhythm problems. The findings are in the full paper.
Recap by typeshit. Post by HeartRhythm on X.
A physio fielding years of peptide questions says strong studies are lacking, while noting that a lack of evidence doesn't prove they fail.
Up to half of participants in the two trials of the experimental drug ended up with only mild sleep apnea, per the post.
Nippard puts the two approved drugs on top for supervised weight loss and holds retatrutide at B-tier until it is approved.
Bloomberg traces how Amgen used genetic data from Iceland to guide its obesity drug research.
A Weird Science riff frames her before and after, crediting GLP-1 medication for taking her from 233 pounds down to 133.
22:37
A biohacking channel walks through the latest retatrutide study results and gives his read on how strong the weight loss figures look.
Loading…